Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Correction - Updated Food Recall Warning - Lee's Tea brand Teas recalled due to Salmonella


OTTAWA, March 29, 2019 /CNW/ - The food recall warning issued on March 28, 2019 has been amended to correctly identify the affected products and updated to include additional product information. The corrections for these products are marked by an asterisk (*).   This additional information was identified during the Canadian Food Inspection Agency's (CFIA) food safety investigation.

Lee's Provisions Inc. is recalling Lee's Tea brand teas from the marketplace due to possible Salmonella contamination. Consumers should not consume the recalled products described below.

The following products have been sold nationally.

Recalled products

 

Brand

Product

Size

UPC

Codes

Lee's Tea

Gold Rush Loose Leaf

105 g

6 28055 21002 3

4-102318

04-23018*

4-102518

2021FE11

2021FE15

04-02011

04-02021

Lee's Tea

Gold Rush Loose Leaf

110 g

6 28055 21002 3

2020DE07

Lee's Tea

Mint Chill Loose Leaf

60 g

6 28055 21003 0

2-102518

02-25018*

02-01019

02-19018*

02-02021

Lee's Tea

Mint Chill Loose Leaf

70 g

6 28055 21003 0

2020DE07

Lee's Tea

Original Loose Leaf

50 g

6 28055 21001 6

2020DE07

2020MR21

Lee's Tea

Original Loose Leaf

60 g

6 28055 21001 6

1-101918

01-19018*

1-102518

01-25018*

Lee's Tea

Pink Chai Loose Leaf

90 g

6 28055 21004 7

3-112018

3-102518

03-25018*

2020DE07

2021JA07

2021JA23

2021FE05

2021FE11

03-02021

03-01019

03-19018*

03-02011

Lee's Tea

Pink Chai Loose Leaf

30 g

6 28055 21014 6

3062718

 

What you should do

If you think you became sick from consuming a recalled product, call your doctor.

Check to see if you have recalled products in your home. Recalled products should be thrown out or returned to the store where they were purchased.

Food contaminated with Salmonella may not look or smell spoiled but can still make you sick. Young children, pregnant women, the elderly and people with weakened immune systems may contract serious and sometimes deadly infections. Healthy people may experience short-term symptoms such as fever, headache, vomiting, nausea, abdominal cramps and diarrhea. Long-term complications may include severe arthritis.

Background

This recall was triggered by the Canadian Food Inspection Agency's (CFIA) inspection activities. The CFIA is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated Food Recall Warnings.

The CFIA is verifying that industry is removing recalled product from the marketplace.

Illnesses

There have been no reported illnesses associated with the consumption of these products.

More information

 

SOURCE Canadian Food Inspection Agency (CFIA)


These press releases may also interest you

at 12:20
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 12:05
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...

at 11:55
The "Infectious Vaccine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 11:40
The "Musculoskeletal Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Musculoskeletal Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the...

at 11:30
The "Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering. Fully revised and updated, the report provides details of option and evaluation deals from 2016 to 2024....



News published on and distributed by: